HS-20093 for osteosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Apr 2025: Trial registered, NCT06935409
  2. 25 Apr 2025: Trial started, NCT06935409

The trials

NCT06935409: Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

State
Completed
Phase
Phase 3
People
122 taking part
Started
25 Apr 2025
Primary completion
17 Jun 2026
Arms
HS-20093
Results
None posted
  1. 20 Apr 2025: Trial registered
  2. 25 Apr 2025: Trial started
  3. 7 Sep 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.